Cover Image

Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

We have developed a manufacturing strategy that can improve the safety and genetic stability of recombinant live-attenuated chimeric dengue vaccine (DENVax) viruses. These viruses, containing the pre-membrane (prM) and envelope (E) genes of dengue serotypes 1-4 in the replicative background of the a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Claire Y-H Huang (Author), Richard M Kinney (Author), Jill A Livengood (Author), Bethany Bolling (Author), John J Arguello (Author), Betty E Luy (Author), Shawn J Silengo (Author), Karen L Boroughs (Author), Janae L Stovall (Author), Akundi P Kalanidhi (Author), Aaron C Brault (Author), Jorge E Osorio (Author), Dan T Stinchcomb (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2013-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
by: Fiona R Strouts, et al.
Published: (2016)

Development and evaluation of a tetravalent botulinum vaccine
by: Dan-Yang Shi, et al.
Published: (2022)

A recombinant live attenuated tetravalent vaccine for the prevention of dengue
by: Bruno Guy, et al.
Published: (2017)

Efficacy of tetravalent dengue vaccine: A systematic review and meta-analysis
by: Ashish Wasudeo Khobragade, et al.
Published: (2021)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.
by: Philip K Russell, et al.
Published: (2016)

A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis
by: Julia Tietz, et al.
Published: (2024)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
by: Sanford R Kimmel
Published: (2008)

The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
by: Shibadas Biswal, et al.
Published: (2021)

The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
by: Marta Poźniak, et al.
Published: (2021)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
by: Claire Vigne, et al.
Published: (2017)

An Evaluation of a Continuing Education Program for Family Caregivers of Ventilator-Dependent Children with Spinal Muscular Atrophy (SMA)
by: Deborah S. Boroughs
Published: (2017)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
by: José Cássio de Moraes, et al.
Published: (2022)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021)

The effect of a booster dose of HPV tetravalent vaccine after 51 months: implications for extended vaccination schedules
by: Eduardo Lazcano-Ponce, et al.
Published: (2018)

SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection
by: Carla Zannella, et al.
Published: (2023)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023)

Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines
by: Paolo Bonanni, et al.
Published: (2020)

Single intravitreal administration of a tetravalent siRNA exhibits robust and efficient gene silencing in mouse and pig photoreceptors
by: Shun-Yun Cheng, et al.
Published: (2024)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
by: Philippe Moris, et al.
Published: (2019)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
by: Stefan W Metz, et al.
Published: (2018)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
by: Sophia Gailhardou, et al.
Published: (2016)

Results of a clinical study of the influenza tetravalent inactivated subunit adjuvant vaccine Grippol Quadrivalent in children aged 6 months to 5 years (inclusive)
by: Viktor V. Romanenko, et al.
Published: (2024)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017)

RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
by: Mark Turner, et al.
Published: (2020)

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
by: Scott B. Halstead
Published: (2018)

O'nyong nyong virus molecular determinants of unique vector specificity reside in non-structural protein 3.
by: Kali D Saxton-Shaw, et al.
Published: (2013)

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
by: Susan B. Manoff, et al.
Published: (2019)

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
by: Philippe J Guerin, et al.
Published: (2008)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
by: Vianney Tricou, et al.
Published: (2023)

Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2
by: Shilpa Sharma, et al.
Published: (2021)

Thought Leadership and Women's Liberation Politics
by: Janae Knott
Published: (2022)

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019)

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants
by: Lalitendu Mohanty, et al.
Published: (2017)

Safety of Tetravalent Conjugate Meningococcal Vaccine (Serotypes A, C, Y, W) for 1-4 Years Old Children With Distresses and Chronic Diseases in Closed Healthcare Facility: Cohort Study
by: Alebai U. Sabitov, et al.
Published: (2019)

Robert Toombs Statesman, Speaker, Soldier, Sage
by: Stovall, Pleasant A., 1857-1935

Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms
by: Caroline L. Strasinger, et al.
Published: (2009)

Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms
by: Audra L. Stinchcomb, et al.
Published: (2009)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Shrikant Sharma, et al.
Published: (2018)